VYGR logo

VYGR
Voyager Therapeutics Inc

3,859
Mkt Cap
$230.05M
Volume
507,968.00
52W High
$5.55
52W Low
$2.65
PE Ratio
-1.96
VYGR Fundamentals
Price
$3.99
Prev Close
$3.86
Open
$3.89
50D MA
$3.93
Beta
1.38
Avg. Volume
924,639.23
EPS (Annual)
-$2.04
P/B
1.20
Rev/Employee
$286,340.43
$70.71
Loading...
Loading...
News
all
press releases
Voyager Therapeutics Conference: CEO Calls 2026 "Year of Tau," Eyes BBB Capsid Clinic Debut
Voyager Therapeutics (NASDAQ:VYGR) CEO Al Sandrock outlined several 2026 priorities in a discussion focused on the company's tau-directed pipeline and its newer blood-brain barrier (BBB)-penetrant capsid platform. Sandrock described 2026 as "the year of tau," while also pointing to upcoming clinical...
MarketBeat·10d ago
News Placeholder
More News
News Placeholder
HC Wainwright Analysts Increase Earnings Estimates for VYGR
Voyager Therapeutics, Inc. (NASDAQ:VYGR - Free Report) - Investment analysts at HC Wainwright upped their Q1 2026 EPS estimates for shares of Voyager Therapeutics in a note issued to investors on Tuesday, March 17th. HC Wainwright analyst P. Trucchio now expects that the company will post earnings o...
MarketBeat·14d ago
News Placeholder
Analysts Set Expectations for VYGR Q1 Earnings
Voyager Therapeutics, Inc. (NASDAQ:VYGR - Free Report) - Equities researchers at HC Wainwright issued their Q1 2027 earnings estimates for Voyager Therapeutics in a research report issued to clients...
MarketBeat·15d ago
News Placeholder
Voyager Therapeutics' (VYGR) "Buy" Rating Reaffirmed at HC Wainwright
HC Wainwright restated a "buy" rating and set a $25.00 price objective on shares of Voyager Therapeutics in a research report on Tuesday...
MarketBeat·15d ago
News Placeholder
Voyager Therapeutics (NASDAQ:VYGR) Upgraded to Hold at Wall Street Zen
Wall Street Zen raised shares of Voyager Therapeutics from a "sell" rating to a "hold" rating in a research report on Saturday...
MarketBeat·19d ago
News Placeholder
Voyager Therapeutics (VYGR) Reports Q4 Loss, Beats Revenue Estimates
Voyager Therapeutics (VYGR) delivered earnings and revenue surprises of +15.08% and +57.97%, respectively, for the quarter ended December 2025. Do the numbers hold clues to what lies ahead for the stock?
Zacks·23d ago
News Placeholder
Voyager Therapeutics (NASDAQ:VYGR) Announces Earnings Results, Beats Expectations By $0.08 EPS
Voyager Therapeutics (NASDAQ:VYGR - Get Free Report) issued its quarterly earnings results on Monday. The company reported ($0.46) EPS for the quarter, topping the consensus estimate of ($0.54) by...
MarketBeat·23d ago
News Placeholder
Lineage Cell (LCTX) Reports Break-Even Earnings for Q4
Lineage Cell (LCTX) delivered earnings and revenue surprises of +100.00% and +187.81%, respectively, for the quarter ended December 2025. Do the numbers hold clues to what lies ahead for the stock?
Zacks·27d ago
News Placeholder
Voyager Therapeutics (VYGR) to Release Quarterly Earnings on Tuesday
Voyager Therapeutics (NASDAQ:VYGR) will be releasing its Q4 2025 earnings before the market opens on Tuesday, March 10. (View Earnings Report at...
MarketBeat·30d ago
News Placeholder
Voyager Therapeutics Touts Tau, Gene Therapy and NeuroShuttle Roadmap, Sees Cash Runway Into 2028
Voyager Therapeutics (NASDAQ:VYGR) outlined what CEO Al Sandrock described as three pillars of value for the year ahead during a discussion at Oppenheimer's 36th Annual Life Science Conference...
MarketBeat·1mo ago
<
1
2
...
>

Latest VYGR News

View
Top Discussions

Advertisement|Remove ads.

Advertisement|Remove ads.